Get the Stockscreener App
27.49
3.97%
1.05
After Hours:
26.94
-0.55
-2.00%
Bridgebio Pharma Inc stock is traded at $27.49, with a volume of 2.48M.
It is up +3.97% in the last 24 hours and up +15.31% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$26.44
Open:
$26.53
24h Volume:
2.48M
Relative Volume:
1.08
Market Cap:
$5.00B
Revenue:
$219.12M
Net Income/Loss:
$-453.82M
P/E Ratio:
-7.0487
EPS:
-3.9
Net Cash Flow:
$-419.68M
1W Performance:
+19.31%
1M Performance:
+15.31%
6M Performance:
-1.61%
1Y Performance:
-7.72%
1-Day Range:
$26.25
$28.20
1-Week Range:
$22.47
$30.51
52-Week Range:
$21.62
$44.32
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
27.49 | 5.00B | 219.12M | -453.82M | -419.68M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
HC Wainwright Analysts Increase Earnings Estimates for BBIO - MarketBeat
What is Leerink Partnrs' Forecast for BBIO FY2024 Earnings? - MarketBeat
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug - MSN
BridgeBio Pharma (FRA:2CL) Total Liabilities : €1,696.9 Mil (As of Sep. 2024) - GuruFocus.com
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby - Marketscreener.com
BridgeBio's Attruby (Acoramidis) Approval Could Pave Way for Long-Term Profitability - Morningstar
Leerink Partnrs Expects Weaker Earnings for BridgeBio Pharma - MarketBeat
BridgeBio price target raised to $45 from $42 at BofA - Yahoo Finance
Eagle Asset Management Inc. Lowers Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Algert Global LLC Has $3.47 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Massachusetts Financial Services Co. MA Grows Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds - MSN
BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer - MSN
FDA approves BridgeBio’s Attruby for ATTR-CM treatment - Indian Pharma Post
BridgeBio Pharma Receive FDA Nod for Attruby - Diagnostic and Interventional Cardiology
BridgeBio’s Attruby Could Benefit From ‘Best-Case’ Label, Lower Price - Citeline
BridgeBio Soars After Drug Gets Nod in Rare Heart Condition - MSN
Health Care Up Amid Cyclical Bias -- Health Care Roundup - Marketscreener.com
Bridgebio, with FDA approval, faces Pfizer in ATTR - BioWorld Online
Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race - FirstWord Pharma
BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug - Investor's Business Daily
Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY™ (acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis - Yahoo Finance
Gold Down Over 3%; Rigetti Computing Shares Spike Higher - Benzinga
FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug - MedCity News
BridgeBio's SWOT analysis: genetic disease fighter's stock faces pivotal moment - Investing.com
BridgeBio stock retains Overweight; Piper Sandler highlights competitive pricing for Attruby - Investing.com
US FDA approves BridgeBio's drug for rare heart condition (Nov 22) - Reuters.com
BridgeBio stock remains Market Perform; BMO cites key milestone in regulatory progress - Investing.com
BridgeBio shares surge 25% on FDA approval of Attruby - Investing.com
FDA approves Palo Alto biotech's heart disease drug - The Business Journals
BridgeBio shares maintain buy rating on positive Attruby launch outlook - Investing.com
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up Following Analyst Upgrade - MarketBeat
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday - Inkl
BridgeBio Soars After Drug Gets Nod in Serious Heart Condition - MSN
BridgeBio price target raised to $48 from $45 at Scotiabank - TipRanks
BridgeBio shares retain Buy rating as H.C. Wainwright highlights Attruby FDA approval - Investing.com
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug - Yahoo! Voices
BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby - MarketWatch
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of America - MarketBeat
HC Wainwright Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy - FiercePharma
FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM - PMLiVE
BridgeBio gets FDA nod for Attruby to treat ATTR-CM patients - World Pharmaceutical Frontiers
BridgeBio Pharma Obtains FDA Approval of Attruby - Marketscreener.com
BBIO (BridgeBio Pharma) Long-Term Capital Lease Obligation : $5.8 Mil (As of Sep. 2024) - GuruFocus.com
BridgeBio’s Attruby wins FDA approval - The Pharma Letter
BridgeBio poised to challenge Pfizer after Attruby approval - pharmaphorum
BridgeBio: Next Chapter Begins After Attruby Approval - Seeking Alpha
B. Metzler seel. Sohn & Co. Holding AG Buys Shares of 36,603 BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Jennison Associates LLC Buys New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bridgebio Pharma Inc Stock (BBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Secretary, Treasurer & CFO |
Nov 19 '24 |
Sale |
22.41 |
4,156 |
93,137 |
93,758 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):